Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Communities
“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” says Cybin Chief Clinical Officer Dr. Alex Belser.
Cybin
Psychedelic Business Spotlight: November 12
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’
Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser
“Something that people used to speak about only in whispers is now standard policy,” says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.
Psychedelic Business Spotlight: October 29
This week in psychedelic business news: MindMed’s MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
FDA Authorizes Cybin Device to Quantify Psychedelics’ Effects on the Brain
“This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding,” says Cybin’s chief clinical officer.
Psychedelic Business Spotlight: October 22
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Psychedelic Business Spotlight: October 15
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic Compounds
CEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions of people suffering around the globe.
End of content
End of content